BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3439205)

  • 1. [Treatment of peripheral arterial occlusive disorders with rheologically active measures].
    Turowski A; Schmidt HH; Sternitzky R
    Z Arztl Fortbild (Jena); 1987; 81(17):883-8. PubMed ID: 3439205
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood rheology in peripheral occlusive disease. Effects of hemodilution and pentoxifylline].
    Angelkort B
    Wien Med Wochenschr; 1986; 136 Spec No():29-35. PubMed ID: 3548089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Whole blood viscosity in patients with acral arterial occlusive diseases and their modification by rheologically active drugs].
    Runge E; Thiele P
    Z Gesamte Inn Med; 1987 Mar; 42(5):137-41. PubMed ID: 3590891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of I.V. application of pentoxifylline on the viscoelasticity of blood in patients with peripheral vascular disorders.
    Chmiel H; Anadere I; Heimburg P
    Ric Clin Lab; 1981; 11 Suppl 1():189-96. PubMed ID: 7188108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
    Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
    Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Spitzer S; Gerhards M; Waldhausen P; Wenzel E
    Wien Med Wochenschr; 1989 Sep; 139(17):396-401. PubMed ID: 2480029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hemodilution in peripheral arterial occlusive disease--study comparing 3 different variants of hemodilution].
    Weidinger P; Bilek M; Tekusch A
    Vasa Suppl; 1990; 30():137-8. PubMed ID: 2075564
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of pentoxifylline on blood viscosity and peripheral hemodynamics in patients with peripheral occlusive arteriopathies].
    Guerrini M; Pecchi S; Rossi C; Cappelli R; Pieragalli D; Acciavatti A
    Ric Clin Lab; 1981; 11 Suppl 1():265-79. PubMed ID: 7188114
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic efficacy of pentoxifylline in peripheral artery diseases: its clinical value].
    Benignetti G; Fabbri F; Benvenuti C
    Clin Ter; 1983 Feb; 104(4):297-304. PubMed ID: 6861465
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic consequences of hemorheologic research].
    Ernst E
    Wien Med Wochenschr; 1989 Dec; 139(24):569-80. PubMed ID: 2696217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood rheology in chronic arterial occlusive disease as influenced by vasodilators (author's transl)].
    Störmer B; Kleinschmidt F; Loose D; Kremer K
    Dtsch Med Wochenschr; 1978 Apr; 103(16):694-8. PubMed ID: 639718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Kinetic effects of 6% hydroxyethyl starch 200.000/0.6-0.66 in hypervolemic hemodilution].
    Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
    Acta Med Austriaca; 1991; 18 Suppl 1():20-2. PubMed ID: 1719728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemorheologic conditions in patients with cerebrovascular disease altered by treatment with pentoxifylline.
    Ott E; Lechner H
    Ric Clin Lab; 1981; 11 Suppl 1():253-6. PubMed ID: 7188113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Walk training and drug therapy in peripheral arterial occlusive disease. A randomized, prospective, placebo-controlled double-blind study].
    Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
    Dtsch Med Wochenschr; 1987 May; 112(22):873-8. PubMed ID: 3556133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypervolemic hemodilution with medium molecular-weight hydroxyethyl starch: effect of duration of administration on viscoelasticity of blood in IIa and IIb peripheral arterial occlusive disease].
    Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
    Acta Med Austriaca; 1991; 18 Suppl 1():45-7. PubMed ID: 1719731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induced hemodilution as a new concept in the therapy of peripheral circulatory disorders].
    Rieger H
    Internist (Berl); 1982 Jul; 23(7):375-82. PubMed ID: 7049999
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemorheologic therapy in peripheral arterial occlusive disease].
    Kiesewetter H; Jung F
    Fortschr Med; 1984 Oct; 102(37):921-4. PubMed ID: 6500451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic occlusive arterial disease with pentoxifylline: changes in clinical and haemodynamic parameters.
    Schweiger H; Ortmeier CJ
    Pharmatherapeutica; 1989; 5(5):298-304. PubMed ID: 2526340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemodilution in peripheral arterial occlusive disease. Placebo controlled randomized double-blind study with hydroxyethyl starch or dextran].
    Ernst E; Kollar L; Matrai A
    Acta Med Austriaca; 1991; 18 Suppl 1():27-9. PubMed ID: 1719730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
    Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.